Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Target ID: TTDS00035

Target Information
NameBeta adrenergic receptor    
Type of targetSuccessful target    
SynonymsBeta-Adrenoceptor    
DiseaseNoninsulin-dependent diabetes mellitus    [1]
Obesity    [1]
Schizophrenia    [2]
Drug(s)ArbutamineApprovedCoronary artery disease [3]
BethanidineApprovedHypertension[4]
BretyliumApprovedAV (atrioventricular) heart block[5][6]
CarteololApprovedHypertension[7][8]
CryptenamineApprovedHypertension[9][10]
DipivefrinApprovedOpen-angle glaucoma[11]
EpinephrineApprovedAnaphylaxis and sepsis[12]
IsoetharineApprovedAsthma[13][14]
IsoproterenolApprovedBradycardia or heart block[15][16]
LevobunololApprovedOpen-angle glaucoma[17]
MetipranololApprovedOpen-angle glaucoma and ocular hypertension[18]
NadololApprovedHigh blood pressure and angina[19]
NorepinephrineApprovedSeptic shock and neurogenic shock[20]
PenbutololApprovedHypertension[21][22]
PindololApprovedHypertension and angina[23]
PropranololApprovedMigraine[24]
RitodrineApprovedPremature labour[25][26]
TimololApprovedHigh blood pressure[27][28][29]
BioChemical ClassTransmembrane protein    
PathwayCalcium signaling pathway
Neuroactive ligand-receptor interaction
Related US Patent6,297,382
6,316,443
6,352,992
6,399,605
6,414,030
6,441,181
Target ValidationClick to Find Target Validation Information.    
AgonistBRL 35135[1]
Carazolol[30]
Carteolol[7][8]
Epinephrine[12]
Isoetharine[13][14]
Isoprenaline[1]
Isoproterenol[15][16]
Ritodrine[25][26]
Antagonist (-)-propranolol[24]
Bethanidine[4]
Bretylium[5][6]
Cryptenamine[9][10]
Dipivefrin[11]
Levobunolol[17]
Metipranolol[18]
Nadolol[19]
Penbutolol[21][22]
Pindolol[23]
Propranolol[24]
Timolol[27][28][29]
StimulatorArbutamine[3]
Norepinephrine[20]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol. 1996 Sep;42(3):291-300. To Reference
Ref 2Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr. 2004 May;9(5):350-5. To Reference
Ref 3Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47. To Reference
Ref 4Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981 Aug;141(9):1125-7. To Reference
Ref 5Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10. To Reference
Ref 6Dissociation of autonomic controls of heart rate in weaning-aged borderline hypertensive rats by perinatal NaCl. J Auton Nerv Syst. 1990 Mar;29(3):219-26. To Reference
Ref 7Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. To Reference
Ref 8Effects of prolonged treatment with beta-adrenoceptor antagonist, carteolol on systemic and regional hemodynamics in stroke-prone spontaneously hypertensive rats. J Pharmacobiodyn. 1991 Feb;14(2):94-100. To Reference
Ref 9Regulation of a presynaptic adenylate cyclse from bovine cerebellum by beta-adrenergic receptors. Biochim Biophys Acta. 1980 Jun 20;599(1):167-74. To Reference
Ref 10Pharmacology and mechanism of action of cryptenamine. J Pharm Sci. 1966 Sep;55(9):888-93. To Reference
Ref 11Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996 May;5(3):146-53. To Reference
Ref 12Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77. Epub 2009 May 21. To Reference
Ref 13Adrenergic receptor agonists. Conformation of erythro and threo forms of compounds related to ephedrine and isoetharine. Acta Pharm Suec. 1977;14(1):30-6. To Reference
Ref 14Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int J Obes (Lond). 2005 Jul;29(7):746-54. To Reference
Ref 15Adenoprotection of the heart involves phospholipase C-induced activation and translocation of PKC-epsilon to RACK2 in adult rat and mouse. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H718-25. Epub 2009 Jun 12. To Reference
Ref 16Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res. 2007 Feb 16;100(3):391-8. Epub 2007 Jan 18. To Reference
Ref 17Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84. To Reference
Ref 18Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005 Jun;21(3):175-81. To Reference
Ref 19Bleeding caused by portal hypertension. Gastroenterol Clin North Am. 2005 Dec;34(4):623-42. To Reference
Ref 20Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31. To Reference
Ref 21beta-Adrenergic receptor blockers--a group of chiral drugs: different effects of each enantiomer. Ceska Slov Farm. 2002 May;51(3):121-8. To Reference
Ref 22Decrease in penbutolol central response as a cause of changes in its serum protein binding. J Pharm Pharmacol. 1990 Mar;42(3):164-6. To Reference
Ref 23Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. Epub 2007 Apr 12. To Reference
Ref 24Beta-blockers in the treatment of hypertension: are there clinically relevant differences? Postgrad Med. 2009 May;121(3):90-8. To Reference
Ref 25Acute tocolysis for uterine activity reduction in term labor: a review. Obstet Gynecol Surv. 2008 Jun;63(6):383-8; quiz 405. To Reference
Ref 26Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence. J Med Chem. 2001 Apr 26;44(9):1436-45. To Reference
Ref 27Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95. To Reference
Ref 28Blockade of beta-adrenergic receptors prevents amphetamine-induced behavioural sensitization in rats: a putative role of the bed nucleus of the stria terminalis. Int J Neuropsychopharmacol. 2005 Dec;8(4):569-81. Epub 2005 Apr 19. To Reference
Ref 29A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects. Br J Clin Pharmacol. 1997 Mar;43(3):301-8. To Reference
Ref 30Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543